Related Experiment Videos
[Molecular markers for transitional cell carcinoma of bladder]
Harefuah
|August 12, 2003
Summary
Accurate urinary markers are crucial for detecting and monitoring superficial transitional cell carcinoma (TCC). While some markers show higher sensitivity than urine cytology, their specificity varies, impacting clinical utility.
Area of Science:
- Urology
- Oncology
- Biochemistry
Context:
- Superficial transitional cell carcinoma (TCC) presents high recurrence and progression rates.
- Accurate diagnostic and follow-up tools for TCC are essential.
- Urine cytology is the established clinical standard for TCC detection.
Purpose:
- To review and compare the properties and clinical utility of various molecular urinary markers for TCC.
- To evaluate the diagnostic yield of these markers against traditional urine cytology.
- To assess the potential role of novel markers in TCC management.
Summary:
- Older markers (BTA, NMP22) offer higher sensitivity but lower specificity than cytology.
- Fibrinogen degradation products (FDP) show improved sensitivity for low-grade tumors but poor specificity.
- Newer markers like telomerase, Hyaluronidase (HA-HAase), and CK20 demonstrate promising results, with CK20 showing potential for detecting premalignant conditions and predicting recurrence.
Impact:
- Current urinary markers have uncertain roles in replacing cystoscopy or urine cytology for TCC follow-up and hematuria workup.
- Future applications may involve marker panels for TCC management and screening high-risk populations (e.g., smokers, occupational exposures).
- Further research is needed to validate novel markers for widespread clinical adoption.